Senior Director, Alliance Management and Strategic Partnerships

Does it excite you to work with partners to bring new medicines to the market and to patients, and do you have experience with taking partnerships from early science through to launch? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague. Your new position This Senior Director position reports to the SVP for Alliance Management, within a growing area of Commercial. The ambition is to evolve the mandate from ensuring partnerships are well governed and deliver against contractual obligations to maximizing the strategic, scientific and commercial value of our external partnerships across the asset lifecycle: from early science through development, regulatory approval, launch and lifecycle management. As we grow, the position offers the opportunity to build a "partner-to-market" value proposition for the entire organization and to shape the area that delivers it. We offer exciting responsibilities: Shape and drive the partner-to-market agenda, keeping the route to market in focus and contributing to the strategy, operating model and growth of the area Lead strategic partnership assessments, from partner identification and deal thesis development to close collaboration with Business Development and the identification of portfolio and capability gaps that partnerships can address Maximize the value of partnered assets through strong alliance governance, timely milestone delivery and proactive risk management across the partnership portfolio Drive cross-functional alignment between Zealand teams and partners, and resolve escalations and conflicts constructively and swiftly Prepare partnerships for commercial success through launch readiness, market access collaborations and co-commercialization models Unlock lifecycle expansion opportunities with partners, including new indications that extend the value of Zealand assets Your profile You are motivated by the path from molecules to market, and by combining Zealand's strengths with those of our partners to reach patients faster and further. Alliance management experience is a strength, and you have a genuine motivation to drive partnership progress with the patient always in view. You are a strategic and commercially minded partner who builds trust easily, influences without relying on formal authority, and is energized by building something new in a growing organization. Curiosity, resilience and a bold, collaborative approach come naturally to you. Minimum 10 years of experience in biopharma or big pharma, within partnering, business development, alliance management, commercial or development roles Deep understanding of drug development and commercialization, demonstrated through hands-on experience from regulatory approval, launch readiness, market access or co-commercialization, and the ability to connect early scientific decisions to commercial outcomes Strong strategic and commercial acumen, including deal structures, partnership economics and deal thesis development, with the ability to assess where a partnership creates the most value for patients and for Zealand across the asset lifecycle Solid understanding of US market dynamics, including pricing, payer and market access considerations that shape partnered commercial strategies Solid understanding and experience working with Chinese market is an advantage Ability to challenge early science and clinical development programs with the end product in mind, ideally with experience within obesity and metabolic health Your new team Alliance Management reports to the Executive Vice President for Commercial and works at the interface between our partners and our internal functions across research, development, regulatory, commercial and business development Let's bond and be bold We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let's bond and be bold. Interested in bonding with us? Then please apply no later than 8 November 2026 or as soon as possible. The applications will be reviewed as they come in. While a cover letter is not required, please include a few sentences in your CV explaining your motivation for applying. We are committed to an inclusive recruitment process and welcome applications from all job applicants. About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com. Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.